Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 4:12:841381.
doi: 10.3389/fonc.2022.841381. eCollection 2022.

The Emerging Role of PRMT6 in Cancer

Zhixian Chen  1   2 , Jianfeng Gan  1   2 , Zhi Wei  1   2 , Mo Zhang  1   2 , Yan Du  1   2 , Congjian Xu  1   2 , Hongbo Zhao  1   2
Affiliations
Review

The Emerging Role of PRMT6 in Cancer

Zhixian Chen et al. Front Oncol. .

Abstract

Protein arginine methyltransferase 6 (PRMT6) is a type I PRMT that is involved in epigenetic regulation of gene expression through methylating histone or non-histone proteins, and other processes such as alternative splicing, DNA repair, cell proliferation and senescence, and cell signaling. In addition, PRMT6 also plays different roles in various cancers via influencing cell growth, migration, invasion, apoptosis, and drug resistant, which make PRMT6 an anti-tumor therapeutic target for a variety of cancers. As a result, many PRMT6 inhibitors are being utilized to explore their efficacy as potential drugs for various cancers. In this review, we summarize the current knowledge on the function and structure of PRMT6. At the same time, we highlight the role of PRMT6 in different cancers, including the differentiation of its promotive or inhibitory effects and the underlying mechanisms. Apart from the above, current research progress and the potential mechanisms of PRMT6 behind them were also summarized.

Keywords: PRMT6; PRMT6 inhibitors; arginine methylation; cancers; regulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline of PRMT6 research. A brief history of functional and pharmacological studies of PRMT6.
Figure 2
Figure 2
Structural attributes of PRMT6. (A) Overall crystal structure of human PRMT6 (PDB: 6W6D, this work) in complex with SAH (marine yellow). (B) Structual superimposition of the conserved motif from PRMT6 (Motif: YYECY).
Figure 3
Figure 3
Promoting and suppressing effects of PRMT6 on different cancers. OC, ovarian cancer; HCC, hepatocellular carcinoma; MM, melanoma; PC, prostate cancer; BC, breast cancer; EMC, endometrial carcinoma; CRC, colorectal cancer; SaOS, osteosarcoma; GC, gastric cancer; CC, cervical cancer; LC, lung cancer; RMS, rhabdomyosarcoma; GBM, glioblastoma; AR, androgen receptor; Polβ, DNA polymerase β.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mohammad HP, Barbash O, Creasy CL. Targeting Epigenetic Modifications in Cancer Therapy: Erasing the Roadmap to Cancer. Nat Med (2019) 25(3):403–18. doi: 10.1038/s41591-019-0376-8 - DOI - PubMed
    1. Brostoff S, Eylar E. Localization of Methylated Arginine in the A1 Protein From Myelin. Proc Natl Acad Sci United States America (1971) 68(4):765–9. doi: 10.1073/pnas.68.4.765 - DOI - PMC - PubMed
    1. Walsh G. Post-Translational Modifications of Protein Biopharmaceuticals. Drug Discovery Today (2010) 15(17-18):773–80. doi: 10.1016/j.drudis.2010.06.009 - DOI - PubMed
    1. Morales Y, Caceres T, May K, Hevel JM. Biochemistry and Regulation of the Protein Arginine Methyltransferases (PRMTs). Arch Biochem Biophys (2016) 590:138–52. doi: 10.1016/j.abb.2015.11.030 - DOI - PubMed
    1. Yang Y, Bedford MT. Protein Arginine Methyltransferases and Cancer. Nat Rev Cancer (2013) 13(1):37–50. doi: 10.1038/nrc3409 - DOI - PubMed